Kroeger Christopher A. sold $5.4M of MPLT
Kroeger Christopher A. (Chief Executive Officer) sold 147,639 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $36.87 ($36.00–$37.96, $5.44M total) across 7 trades over 2026-07-15 to 2026-07-17.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale is a sentiment input for traders monitoring insider behavior, but it does not change the company’s disclosed fundamentals in this text.
Market read
Traders may reassess near-term sentiment around MPLT based on CEO selling size and timing, but there is no accompanying operational update here.
What to watch
The filing does not state a reason for the sale and explicitly notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty rather than confirm bearish intent.
Background
The article is an SEC Form 4 insider transaction disclosure for MapLight Therapeutics, Inc.
Ticker impact
MapLight Therapeutics CEO Christopher A. Kroeger sold about 147,639 shares in open-market trades for roughly $5.44M, per Form 4.
Likely limited, short-lived impact unless follow-on filings or company-specific news emerge.
The filing is a primary-source Form 4 showing sale size and price range, but it provides no stated reason, no 10b5-1 plan, and no accompanying operational or guidance change.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity management, especially given multiple small trades across consecutive days, so it may not signal deteriorating fundamentals.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the Form 4 insider sale by its CEO.
- insiderChristopher A. Kroeger
CEO and officer/director who sold shares in open-market transactions.